The epidemiological and economic burden of diabetes in Ghana: A scoping review to inform health technology assessment

Author:

Kazibwe JosephORCID,Gad Mohamed,Abassah-Konadu EmmanuellaORCID,Amankwah Ivy,Owusu RichmondORCID,Gulbi Godwin,Torres-Rueda Sergio,Asare Brian,Vassall Anna,Ruiz FrancisORCID

Abstract

Diabetes remains one of the four major causes of morbidity and mortality globally among non-communicable diseases (NCDs. It is predicted to increase in sub–Saharan Africa by over 50% by 2045. The aim of this study is to identify, map and estimate the burden of diabetes in Ghana, which is essential for optimising NCD country policy and understanding existing knowledge gaps to guide future research in this area. We followed the Arksey and O’Malley framework for scoping reviews. We searched electronic databases including Medline, Embase, Web of Science, Scopus, Cochrane and African Index Medicus following a systematic search strategy. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews was followed when reporting the results. A total of 36 studies were found to fulfil the inclusion criteria. The reported prevalence of diabetes at national level in Ghana ranged between 2.80%– 3.95%. At the regional level, the Western region reported the highest prevalence of diabetes: 39.80%, followed by Ashanti region (25.20%) and Central region at 24.60%. The prevalence of diabetes was generally higher in women in comparison to men. Urban areas were found to have a higher prevalence of diabetes than rural areas. The mean annual financial cost of managing one diabetic case at the outpatient clinic was estimated at GHS 540.35 (2021 US $194.09). There was a paucity of evidence on the overall economic burden and the regional prevalence burden. Ghana is faced with a considerable burden of diabetes which varies by region and setting (urban/rural). There is an urgent need for effective and efficient interventions to prevent the anticipated elevation in burden of disease through the utilisation of existing evidence and proven priority-setting tools like Health Technology Assessment (HTA).

Funder

Bill and Melinda Gates Foundation

Publisher

Public Library of Science (PLoS)

Reference63 articles.

1. World Health Organization. Noncommunicable diseases: Mortality. 2022 [cited 28 Dec 2022]. https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/ncd-mortality

2. International Diabetes Federation. Facts & figures. 9 Dec 2021 [cited 28 Dec 2022]. https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html

3. International Diabetes Federation. IDF Diabetes Atlas | Tenth Edition. 2021. https://diabetesatlas.org/

4. World Health Organization. ICD-11 for Mortality and Morbidity Statistics: 5A10 Type 1 diabetes mellitus. Feb 2022 [cited 28 Dec 2022]. https://icd.who.int/browse11/l-m/en#http%3A%2F%2Fid.who.int%2Ficd%2Fentity%2F1651053999

5. International Diabetes Federation. What is diabetes. 7 Jul 2022 [cited 28 Dec 2022]. https://www.idf.org/aboutdiabetes/what-is-diabetes.html

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3